Great Lakes Advisors LLC Takes $1.41 Million Position in Aktis Oncology $AKTS

Posted by Francis Steltz on Aug 22nd, 2026

Great Lakes Advisors LLC bought a new position in shares of Aktis Oncology (NASDAQ:AKTS – Free Report) in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor bought 43,612 shares of the technology company’s stock, valued at approximately $1,406,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in AKTS. State of Wyoming purchased a new stake in Aktis Oncology in the 2nd quarter worth $32,000. Deutsche Bank AG lifted its holdings in Aktis Oncology by 49.3% during the second quarter. Deutsche Bank AG now owns 21,022 shares of the technology company’s stock valued at $678,000 after purchasing an additional 6,942 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of Aktis Oncology by 14.8% in the second quarter. Bank of New York Mellon Corp now owns 49,250 shares of the technology company’s stock valued at $1,587,000 after purchasing an additional 6,349 shares during the period. Finally, BlackRock Inc. grew its position in shares of Aktis Oncology by 7.9% in the second quarter. BlackRock Inc. now owns 2,278,358 shares of the technology company’s stock valued at $73,431,000 after purchasing an additional 166,231 shares during the period. Hedge funds and other institutional investors own 28.84% of the company’s stock.

Wall Street Analyst Weigh In

AKTS has been the topic of a number of research reports. William Blair assumed coverage on shares of Aktis Oncology in a research note on Wednesday, April 29th. They issued an “outperform” rating on the stock. BMO Capital Markets began coverage on Aktis Oncology in a report on Tuesday. They set an “outperform” rating and a $37.00 target price for the company. Weiss Ratings upgraded Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, June 23rd. Raymond James Financial assumed coverage on Aktis Oncology in a research note on Monday, June 15th. They issued a “strong-buy” rating and a $40.00 price target on the stock. Finally, JPMorgan Chase & Co. boosted their price target on Aktis Oncology from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 14th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $35.00.

Check Out Our Latest Report on Aktis Oncology

Aktis Oncology Trading Up 0.3%

AKTS opened at $24.07 on Friday. Aktis Oncology has a twelve month low of $14.72 and a twelve month high of $34.19. The firm has a market capitalization of $1.29 billion and a PE ratio of -29.35. The firm’s 50-day moving average price is $25.49 and its 200 day moving average price is $21.29.

Aktis Oncology (NASDAQ:AKTS – Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The technology company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.01). The business had revenue of $3.38 million for the quarter, compared to the consensus estimate of $2.70 million. As a group, analysts predict that Aktis Oncology will post -1.8 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Ken Herrmann sold 4,856 shares of the stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $24.56, for a total value of $119,263.36. Following the completion of the sale, the director owned 3,506 shares of the company’s stock, valued at approximately $86,107.36. This trade represents a 58.07% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 3.30% of the stock is owned by company insiders.

Aktis Oncology Company Profile

(Free Report)

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.